(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.
Alzamend Neuro's earnings in 2026 is -$7,632,109.On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$10,090,173, with the lowest ALZN earnings forecast at -$9,694,480, and the highest ALZN earnings forecast at -$10,386,943. On average, 3 Wall Street analysts forecast ALZN's earnings for 2028 to be -$11,797,741, with the lowest ALZN earnings forecast at -$11,335,084, and the highest ALZN earnings forecast at -$12,144,733.
In 2029, ALZN is forecast to generate -$3,337,519 in earnings, with the lowest earnings forecast at -$3,206,636 and the highest earnings forecast at -$3,435,681.